论文部分内容阅读
目的探讨肿瘤标志物血清癌胚抗原(CEA)以及肿瘤相关抗原199(CA-199)对于预测乳腺癌患者应用吉西他滨化疗的效果。方法选取吉林省人民医院2011年1月至2014年1月收治的乳腺癌患者资料43例,化疗前后对患者的血清CEA和CA-199进行动态监测,分析其动态水平变化以及总生存时间、无进展生存时间的关系。结果血清CEA和A-199的基线水平对于患者的总生存时间以及无进展生存时间无明显影响,化疗后血清CEA以及CA-199下降≥25%者相比于血清CEA和CA-199无下降以及下降<25%者,其总生存时间以及无进展生存时间明显延长,组间比较差异有统计学意义(P<0.05)。结论对于接受吉西他滨化疗的乳腺癌患者,通过对其血清CEA和CA-199进行检测,可以预测其总生存时间以及无进展生存时间。
Objective To investigate the effect of tumor marker serum CEA and tumor-associated antigen 199 (CA-199) on the prediction of gemcitabine chemotherapy in breast cancer patients. Methods Forty-three patients with breast cancer who were admitted to Jilin Provincial People’s Hospital from January 2011 to January 2014 were selected. The serum CEA and CA-199 were monitored before and after chemotherapy. The changes of their dynamic level and the total survival time were analyzed. Progressive survival time of the relationship. Results The baseline levels of serum CEA and A-199 had no significant effect on the overall survival and progression-free survival of patients. After chemotherapy, serum CEA and CA-199 decreased by 25% or more compared with serum CEA and CA-199 Decreased 25%, the total survival time and progression-free survival time was significantly longer, the difference between the two groups was statistically significant (P <0.05). Conclusions For patients with breast cancer undergoing gemcitabine chemotherapy, their serum CEA and CA-199 levels are predictive of overall and progression-free survival.